all participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study: 1. anticipated transfer to another hospital, within 72 hours, which is not a study site 2. expected to not survive beyond 24 hours 3. receiving one of the study drugs at time of enrolment in addition, there will be the below intervention-specific exclusions: randomization who: these will be drug-specific exclusions; patients will still be eligible for randomization in randomization who to the other available study drugs (in randomization who or subsequent randomizations). artesunate: 1. known hypersensitivity to artesunate imatinib: 1. pregnant or breastfeeding; 2. known hypersensitivity to imatinib; 3. liver transaminases (either alt or ast) \> 5x upper limit of normal infliximab: 1. known moderate or severe heart failure, per treating clinician, defined as new york heart association (nyha) class iii or iv 2. known or suspected active tuberculosis 3. known hypersensitivity to infliximab randomization lsalt: 1. known hypersensitivity or prior use of lsalt peptide. 2. pregnant or breastfeeding randomization dex: 1. receiving glucocorticoids for a specific, non-covid-19 indication

all participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study: 1. anticipated transfer to another hospital, within 72 hours, which is not a study site 2. expected to not survive beyond 24 hours 3. receiving one of the study drugs at time of enrolment in addition, there will be the below intervention-specific exclusions: randomization who: these will be drug-specific exclusions; patients will still be eligible for randomization in randomization who to the other available study drugs (in randomization who or subsequent randomizations). artesunate: 1. known hypersensitivity to artesunate imatinib: 1. pregnant or breastfeeding; 2. known hypersensitivity to imatinib; 3. liver transaminases (either alt or ast) \> 5x upper limit of normal infliximab: 1. known moderate or severe heart failure, per treating clinician, defined as new york heart association (nyha) class iii or iv 2. known or suspected active tuberculosis 3. known hypersensitivity to infliximab randomization lsalt: 1. known hypersensitivity or prior use of lsalt peptide. 2. pregnant or breastfeeding randomization dex: 1. receiving glucocorticoids for a specific, non-covid-19 indication

all participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study: anticipated transfer to another hospital, within 72 hours, which is not a study site expected to not survive beyond 24 hours receiving one of the study drugs at time of enrolment in addition, there will be the below intervention-specific exclusions: randomization who: these will be drug-specific exclusions; patients will still be eligible for randomization in randomization who to the other available study drugs (in randomization who or subsequent randomizations). artesunate: 1. known hypersensitivity to artesunate imatinib: pregnant or breastfeeding; known hypersensitivity to imatinib; liver transaminases (either alt or ast) > 5x upper limit of normal infliximab: known moderate or severe heart failure, per treating clinician, defined as new york heart association (nyha) class iii or iv known or suspected active tuberculosis known hypersensitivity to infliximab randomization lsalt: known hypersensitivity or prior use of lsalt peptide. pregnant or breastfeeding randomization dex: 1. receiving glucocorticoids for a specific, non-covid-19 indication

all participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study: anticipated transfer to another hospital, within 72 hours, which is not a study site expected to not survive beyond 24 hours receiving one of the study drugs at time of enrolment in addition, there will be the below intervention-specific exclusions: randomization who: these will be drug-specific exclusions; patients will still be eligible for randomization in randomization who to the other available study drugs (in randomization who or subsequent randomizations). artesunate: 1. known hypersensitivity to artesunate imatinib: pregnant or breastfeeding; known hypersensitivity to imatinib; liver transaminases (either alt or ast) > 5x upper limit of normal infliximab: known moderate or severe heart failure, per treating clinician, defined as new york heart association (nyha) class iii or iv known or suspected active tuberculosis known hypersensitivity to infliximab randomization lsalt: known hypersensitivity or prior use of lsalt peptide. pregnant or breastfeeding randomization dex: 1. receiving glucocorticoids for a specific, non-covid-19 indication

all participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study: anticipated transfer to another hospital, within 72 hours, which is not a study site expected to not survive beyond 24 hours receiving one of the study drugs at time of enrolment in addition, there will be the below intervention-specific exclusions: randomization who: these will be drug-specific exclusions; patients will still be eligible for randomization in randomization who to the other available study drugs (in randomization who or subsequent randomizations). artesunate: 1. known hypersensitivity to artesunate imatinib: pregnant or breastfeeding; known hypersensitivity to imatinib; liver transaminases (either alt or ast) > 5x upper limit of normal infliximab: known moderate or severe heart failure, per treating clinician, defined as new york heart association (nyha) class iii or iv known or suspected active tuberculosis known hypersensitivity to infliximab randomization arbs: hypotension (sap < 100 mmhg or dap < 50 mmhg or map < 65 mmhg) hyperkalemia (> 5.5 mmol/l) acute kidney injury (urine output < 0.5 ml/kg/hr and new creatinine > 200 µmol/l, or increase > 100 µmol/l from baseline creatinine, or gfr < 30 ml/min) use of arb/acei within 7 days of presentation (because randomization to usual care and stopping arb/acei risks complications) pregnant or breastfeeding - a negative pregnancy test for women of child bearing potential have a known allergy to arbs or any component of the drug product have written legal document to withhold life-sustaining treatments (patients not wishing to receive cardiopulmonary resuscitation (cpr) can participate if other medical treatments will be given) have signed a do no resuscitate (dnr) form use of aliskiren in patients with diabetes mellitus (type 1 or type 2) or moderate-severe renal impairment (gfr less than 60ml/min) randomization lsalt: known hypersensitivity or prior use of lsalt peptide. pregnant or breastfeeding randomization dex: 1. receiving glucocorticoids for a specific, non-covid-19 indication

all participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study: anticipated transfer to another hospital, within 72 hours, which is not a study site expected to not survive beyond 24 hours receiving one of the study drugs at time of enrolment in addition, there will be the below intervention-specific exclusions: randomization who: these will be drug-specific exclusions; patients will still be eligible for randomization in randomization who to the other available study drugs (in randomization who or subsequent randomizations). artesunate: 1. known hypersensitivity to artesunate imatinib: pregnant or breastfeeding; known hypersensitivity to imatinib; liver transaminases (either alt or ast) > 5x upper limit of normal infliximab: known moderate or severe heart failure, per treating clinician, defined as new york heart association (nyha) class iii or iv known or suspected active tuberculosis known hypersensitivity to infliximab randomization arbs: hypotension (sap < 100 mmhg or dap < 50 mmhg or map < 65 mmhg) hyperkalemia (> 5.5 mmol/l) acute kidney injury (urine output < 0.5 ml/kg/hr and new creatinine > 200 µmol/l, or increase > 100 µmol/l from baseline creatinine, or gfr < 30 ml/min) use of arb/acei within 7 days of presentation (because randomization to usual care and stopping arb/acei risks complications) pregnant or breastfeeding - a negative pregnancy test for women of child bearing potential have a known allergy to arbs or any component of the drug product have written legal document to withhold life-sustaining treatments (patients not wishing to receive cardiopulmonary resuscitation (cpr) can participate if other medical treatments will be given) have signed a do no resuscitate (dnr) form use of aliskiren in patients with diabetes mellitus (type 1 or type 2) or moderate-severe renal impairment (gfr less than 60ml/min) randomization lsalt: known hypersensitivity or prior use of lsalt peptide. pregnant or breastfeeding randomization dex: 1. receiving glucocorticoids for a specific, non-covid-19 indication

anticipated transfer to another hospital, within 72 hours, which is not a study site expected to not survive beyond 24 hours known allergy to study medication or its components (non-medicinal ingredients) receiving one of the study drugs at time of enrolment

anticipated transfer to another hospital, within 72 hours, which is not a study site expected to not survive beyond 24 hours known allergy to study medication or its components (non-medicinal ingredients) receiving one of the study drugs at time of enrolment

1. anticipated transfer to another hospital, within 72 hours, which is not a study site 2. expected to not survive beyond 24 hours 3. known allergy to study medication or its components (non-medicinal ingredients) 4. receiving one of the study drugs at time of enrolment

1. anticipated transfer to another hospital, within 72 hours, which is not a study site 2. expected to not survive beyond 24 hours 3. known allergy to study medication or its components (non-medicinal ingredients) 4. receiving one of the study drugs at time of enrolment

1. anticipated transfer to another hospital, within 72 hours, which is not a study site 2. expected to not survive beyond 24 hours 3. known allergy to study medication or its components (non-medicinal ingredients) 4. receiving one of the study drugs at time of enrolment 5. known pregnancy

1. anticipated transfer to another hospital, within 72 hours, which is not a study site 2. expected to not survive beyond 24 hours 3. known allergy to study medication or its components (non-medicinal ingredients) 4. receiving one of the study drugs at time of enrolment 5. known pregnancy